Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Reference Study ID Number: BO40729 https://forpatients.roche.com/ 888-662-6728 (U.S. and Canada)
global-roche-genentech-trials@gene.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
Back

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Recruiting

Open to: ALL

Age: 18.0 - N/A

London

Medical Conditions

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or combination/comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Feb 2019 Jul 2028

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).

Intervention Arm Group : Atezolizumab Monotherapy;Combined Agents with Atezolizumab;

Intervention Type : DRUG
Intervention Description : Bevacizumab will be administered as directed per the parent study.

Intervention Arm Group : Combined Agents with Atezolizumab;

Intervention Type : DRUG
Intervention Description : Alectinib will be administered as directed per the parent study.

Intervention Arm Group : Combined Agents with Atezolizumab;

Intervention Type : DRUG
Intervention Description : Cobimetinib will be administered as directed per the parent study.

Intervention Arm Group : Combined Agents with Atezolizumab;Comparator Treatment;

Intervention Type : DRUG
Intervention Description : Vemurafenib will be administered as directed per the parent study.

Intervention Arm Group : Combined Agents with Atezolizumab;Comparator Treatment;

Intervention Type : DRUG
Intervention Description : FAP IL2V will be administered as directed per the parent study.

Intervention Arm Group : Combined Agents with Atezolizumab;

Intervention Type : DRUG
Intervention Description : Venetoclax will be administered as directed per the parent study.

Intervention Arm Group : Combined Agents with Atezolizumab;Comparator Treatment;

Intervention Type : DRUG
Intervention Description : Enzalutamide will be administered as directed per the parent study.

Intervention Arm Group : Combined Agents with Atezolizumab;Comparator Treatment;

Intervention Type : DRUG
Intervention Description : Pembrolizumab will be administered as directed per the parent study.

Intervention Arm Group : Comparator Treatment;

Intervention Type : DRUG
Intervention Description : Sunitinib will be administered as directed per the parent study.

Intervention Arm Group : Comparator Treatment;

Intervention Type : DRUG
Intervention Description : Niraparib will be administered as directed per the parent study.

Intervention Arm Group : Combined Agents with Atezolizumab;Comparator Treatment;

Intervention Type : DRUG
Intervention Description : Cabozantinib will be administered as directed per the parent study.

Intervention Arm Group : Combined Agents with Atezolizumab;

Intervention Type : DRUG
Intervention Description : Pemetrexed will be administered as directed per the parent study.

Intervention Arm Group : Combined Agents with Atezolizumab;Comparator Treatment;

Intervention Type : DRUG
Intervention Description : Paclitaxel will be administered as directed per the parent study.

Intervention Arm Group : Combined Agents with Atezolizumab;Comparator Treatment;

Intervention Type : DRUG
Intervention Description : Emactuzumab will be administered as directed per the parent study.

Intervention Arm Group : Combined Agents with Atezolizumab;

Intervention Type : DRUG
Intervention Description : Rucaparib will be administered as directed per the parent study.

Intervention Arm Group : Combined Agents with Atezolizumab;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Barts Cancer Institute
    London
    E1 2AT

Reference Study ID Number: BO40729 https://forpatients.roche.com/ 888-662-6728 (U.S. and Canada)
global-roche-genentech-trials@gene.com



The study is sponsored by Hoffmann-La Roche



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT03768063
Last updated 13 March 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top